---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024182"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:33:05.544342+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed Q3 net loss $16.5M, cash $154.5M; Phase 2b GAD trial on track for H2 2023 readout

## Summary
- Net loss of $16.5M for Q3 2022 vs $17.2M in Q3 2021; nine-month net loss $51.9M vs $76.2M.
- Cash and equivalents $154.5M as of Sept 30, 2022; expected to fund operations into first half of 2025.
- Raised ~$60M in gross proceeds via at-the-market program and public offering during Q3.
- Phase 2b dose-optimization trial of MM-120 (LSD) in GAD initiated; topline data expected H2 2023.
- Advanced IND-enabling studies for MM-402 (R-MDMA) for autism; Phase 1 planned for 2023.

## SEC filing metadata
- accession: 0000950170-22-024182
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/0000950170-22-024182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/mnmd-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024182
- JSON: https://secwatch.observer/filing/0000950170-22-024182.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024182.txt

## Key facts
- Earnings Releases
  Definium Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $16.5 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $16.5 million
  - Result: reported results
  source text: The net loss for the three months ended September 30, 2022 was $16.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/0000950170-22-024182-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.